Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Burkitt Lymphoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Meningeal Carcinomatosis 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Monocytic, Acute 1Leukemia, Hairy Cell 1Hematopoietic and Lymphatic System Neoplasm 1Glioma 1Glioblastoma 1Germinoma 1Down Syndrome 1Diabetes Insipidus 1Astrocytoma 1

Interventions

Cytarabine 29Busulfan 12Filgrastim 10Daunorubicin 10Peripheral Blood Stem Cell Transplantation 9Idarubicin 9Mitoxantrone 8Methotrexate 8Etoposide 8Cyclosporine 8Gemtuzumab 7Cyclophosphamide 7sargramostim 6fludarabine phosphate 6Azacitidine 6Antilymphocyte Serum 6Decitabine 5tipifarnib 4alvocidib 4Tacrolimus 4Injections 4Cyclosporins 4Biopsy 4Whole-Body Irradiation 3Vorinostat 3Radiotherapy 3Mycophenolic Acid 3Flow Cytometry 3Cytogenetic Analysis 3Clofarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Monocytic, Acute × Spinal Puncture × Clear all
NCT06504459 2026-04-13

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

OHSU Knight Cancer Institute

Phase 2 Recruiting
40 enrolled
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡